Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
HonorHealth, Scottsdale, Arizona University of Arkansas for Medical Sciences, Little Rock, Arkansas Johns Hopkins University, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire Columbia University, New York, New York University of North Carolina Medical Center, Chapel Hill, North Carolina Vanderbilt University, Nashville, Tennessee University of Utah, Salt Lake City, Utah Virginia Commonwealth University, Richmond, Virginia